Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Solazyme (SZYM): It doesn't have a great balance sheet and it doesn't make a lot of money, said Cramer. Don't buy.
Retrophin (RTRX): I think this is a froth stock, said Cramer. It's moved up too much.
Chelsea Therapeutics (CHTP): I like this as a spec, said Cramer. It's a play on Rheumatoid Arthritis.